logo-loader
ANGLE PLC

ANGLE device has lymph node potential, says German research team

"This is another example of our leveraged approach with research customers delivering new applications for Parsortix,” said ANGLE chief executive Andrew Newland

1548749231_x-rays.jpg
Dr Bernhard Polzer and his team at the Fraunhofer Institute for Toxicology and Experimental Medicine provided a glowing recommendation of the device

ANGLE PLC’s (LON:AGL) shares rose on Friday as the firm revealed it has found a potential new application for its liquid biopsy.

Dr Bernhard Polzer and his team at the Fraunhofer Institute for Toxicology and Experimental Medicine, in Regensburg, Germany, found ANGLE’s Parsortix system streamlines the analysis of lymph nodes in melanoma.

WATCH: ANGLE's Parsortix device plays critical role in ground-breaking new cancer research

Not only that, the new process incorporating Parsortix is more sensitive to detecting the spread of the disease to the lymph node, “greatly improving the ability to undertake key molecular analysis on cancer”. 

“It is an added benefit that it also facilitates single cell analysis reducing costs,” said Polzer.

“We previously tried other CTC [circulating tumour cell] systems including antibody-based and membrane systems but these were not suitable for this process."

Polzer’s research has been published as a peer-reviewed publication in the International Journal of Cancer.

"This is another example of our leveraged approach with research customers delivering new applications for Parsortix,” said ANGLE chief executive Andrew Newland.

“There is now the potential for the Parsortix system to be adopted as a standard approach for analysing lymph nodes, which is a requirement for all patients diagnosed with melanoma and several other cancer types."

In late morning trading, shares in ANGLE were 8.2% higher at 59.50p.

 -- Adds share price --

Quick facts: ANGLE PLC

Price: £0.72

Market: AIM
Market Cap: £123.52 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Endorsement for Angle's liquid biopsy system Parsortix

Top stories from the Proactive Investors UK newsroom. Angle (LON:AGL) has received an endorsement for its liquid biopsy system Parsortix from European cancer centre UKE, which says it has potential as a biomarker to test for lung cancer. Security group Westminster (LON:WSG) has signed...

on 21/6/19

2 min read